Table 1.

Demographical profiles and clinical variables at evaluation times in HFEM and CM patients

	HFEM (n = 47)	CM (n = 107)
Age years, mean (SD)	48.9 (11.2)	49.4 (11.2)
Sex % (n females)	78.7 (37)	69.2 (74)
BMI kg/m2, median (25th,75th)	22.00 (20.43,23.63)	23.20 (22.00,25.70)
Baseline MOH % (n)	9.7 (10)	90.3 (93)
Treatment % (n Erenumab)	51.1 (24)	62.6 (67)
MMDs median (25th,75th)
Baseline	11.0 (10.0,13.75)	20.0 (16.0,30.0)
last month	6.0 (4.0,9.0)	9.0 (5.7,14.3)
follow-up 1 month	9.0 (8.0,11.0)	14.5 (10.0,18.0)
follow-up 2 month	10.5 (9.2,11.7)	16.0 (10.7,20.0)
follow-up 3 month	10.5 (9.0,13.5)	15.0 (10.7,22.0)
RR median (25th,75th)
last month	−63.6 (−84.7,-60.0)	−61.1   (-77.3, -40.0)
follow-up 1 month	−42.9 (−87.9,-42.5)	−46.6  (-69.6, -15.4)
follow-up 2 month	−28.6 (−71.5,–20.5)	−40.0 (-55.6, -10.0)
follow-up 3 month	−14.3 (−65.9,-10.3)	−30.0   (-55.0, -6.7)
last month - follow-up 3 difference	−47.7 (−79.5,-17.0)	−25.5 (−47.1,-3.3)
MPI median (25th,75th)
Baseline	12.0 (10.5,14.5)	21.0 (15.0,32.0)
last month	4.0 (2.0,7.0)	7.0 (4.0,13.0)
follow-up 1 month	6.0 (2.5,11.0)	8.0 (5.0,15.0)
follow-up 2 month	9.0 (5.5,12.5)	12.0 (8.0,18.0)
follow-up 3 month	10.0 (6.0,13.5)	15.0 (9.0,22.0)
NRS median (25th,75th)
Baseline	7.5 (7.0,8.0)	7.0 (7.0,8.0)
last month	6.0 (4.0,6.2)	5.0 (4.0,7.0)
follow-up 1 month	6.0 (4.7,7.0)	6.0 (4.0,7.0)
follow-up 2 month	6.0 (4.7,7.0)	6.0 (5.0,7.0)
follow-up 3 month	7.0 (5.0,7.0)	7.0 (5.0,8.0)
Hit-6 median (25th,75th)[n]
Baseline	66.5 (64.7,70.0) [33]	67.0 (64.0,72.0) [83]
last month	51.0 (41.5,60.0) [24]	55.0 (50.0,62.0) [57]
follow-up 1 month	56.0 (31.5,62.3) [20]	60.0 (53.0,66.0) [51]
follow-up 2 month	61.5 (51.5,65.0) [22]	62.0 (53.5,66.5) [51]
follow-up 3 month	60.5 (48.3,65.3) [37]	63.0 (51.0,68.0) [75]